Core Insights - Novo Nordisk announced results from the REDEFINE 4 trial, which investigated the efficacy of CagriSema compared to tirzepatide in individuals with obesity and comorbidities [1][2]. Trial Overview - REDEFINE 4 was an 84-week open-label trial involving 809 participants with a mean baseline body weight of 114.2 kg, comparing CagriSema (2.4 mg cagrilintide and 2.4 mg semaglutide) to tirzepatide (15 mg) [2]. - The trial's design was open-label, meaning both investigators and participants were aware of the treatment being administered [2]. Efficacy Results - Participants treated with CagriSema achieved a weight loss of 23.0% after 84 weeks, compared to 25.5% with tirzepatide [3]. - When applying the treatment-regimen estimand, CagriSema resulted in a weight loss of 20.2%, while tirzepatide achieved 23.6% [3]. - The trial did not meet its primary endpoint of demonstrating non-inferiority in weight loss for CagriSema compared to tirzepatide [3]. Safety Profile - CagriSema exhibited a safe and well-tolerated profile, with the most common adverse events being mild to moderate gastrointestinal issues that diminished over time [4]. Future Developments - The company is optimistic about CagriSema's potential as a first GLP-1/amylin-combination product for obesity treatment, with plans for further trials including REDEFINE 11 and a higher-dose trial [5]. - CagriSema was submitted to the US FDA in December 2025, with a decision expected by late 2026 [5]. - The REDEFINE 11 trial is anticipated to report data in the first half of 2027, while the higher-dose trial is set to begin in the second half of 2026 [5]. About CagriSema - CagriSema is a once-weekly subcutaneous treatment being investigated for adults with obesity and type 2 diabetes, combining cagrilintide and semaglutide to reduce hunger and increase feelings of fullness [7]. About the REDEFINE Programme - The REDEFINE programme is a phase 3 clinical development initiative that includes multiple trials aimed at assessing the efficacy and safety of CagriSema in various populations with obesity [8][9][10][11][12].

Group 1 - The primary goal of the "High Income DIY Portfolios" service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers seven portfolios designed for income investors, including retirees, featuring three buy-and-hold portfolios, three rotational portfolios, and a conservative NPP strategy portfolio [1] - The portfolios include two high-income portfolios, two dividend growth investing (DGI) portfolios, and a conservative NPP strategy portfolio aimed at low drawdowns and high growth [1] Group 2 - The "High Income DIY Portfolios" service includes a total of 10 model portfolios with varying income targets and risk levels, along with buy and sell alerts and live chat support [2] - The investment approach focuses on dividend-growing stocks with a long-term horizon, aiming for 30% lower drawdowns and 6% current income [2] - The service is managed by a financial writer with 25 years of investment experience, emphasizing strategies for stable, long-term passive income [2]

But it's good news for Eli Lilly, too.Novo Nordisk (NVO 2.05%) has struggled over the past year, and the company recently hit another setback when it reported disappointing fourth-quarter results and even worse guidance for fiscal year 2026. The stock price fell by nearly 15% following these developments.However, there are several things to look forward to for Novo Nordisk. One of them is its recent launch of an oral version of its famous weight loss drug, Wegovy. And regarding this product, Novo Nordisk ju ...

Group 1 - Novo Nordisk has nominated Jan van de Winkel and Ramona Sequeira to its board of directors, marking the first additions since a significant management shake-up in 2025 [1] - The company replaced its CEO and overhauled the board, appointing Lars Rebien Sorensen as board chairman, who also chairs the Novo Nordisk Foundation, consolidating power in a dual role [1] - Jan van de Winkel is the co-founder and CEO of Genmab, while Ramona Sequeira previously served as President of the Global Portfolio Division at Takeda Pharmaceutical Company Limited from 2022 to 2025 [1]

Airbus capable of developing a fighter alone, CEO says amid FCAS row | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Item 1 of 2 Guillaume Faury, CEO of Airbus, poses during the Adopt AI International Summit at the Grand Palais in Paris, France, November 26, 2025. REUTERS/Abdul Saboor/File Photo[1/2]Guillaume Faury, CEO of Airbus, poses during the Adopt AI International Summit at the Grand Palais in Paris, France, November 26, 2025 ...

Novo Nordisk (NYSE: NVO) hasn't been getting much love on Wall Street. The stock trades down 66% from its 2024 highs and just took a big hit after the company offered weak guidance for 2026. However, for contrarian dividend investors, Novo Nordisk could be an undervalued opportunity. First, Novo Nordisk's bad news Novo Nordisk was the first company to introduce a GLP-1 weight loss shot. Unfortunately, it couldn't keep up with demand, which allowed compounded versions of the company's Wegovy to be sold. An ...

Core Viewpoint - The article discusses Novo Nordisk (NVO) as presenting a rare investment opportunity after its stock price declined to approximately DKK 300, suggesting potential for long-term outperformance due to its competitive advantages and defensibility [1] Group 1: Company Analysis - Novo Nordisk is highlighted as a high-quality company capable of outperforming the market over the long run due to its economic moat and strong defensibility [1] - The analysis focuses on companies in Europe and North America, without restrictions on market capitalization, indicating a broad investment approach [1] Group 2: Analyst Background - The analyst has a Master's Degree in Sociology with a focus on organizational and economic sociology, and a Bachelor's Degree in Sociology and History, providing a unique perspective on market analysis [1]

2026.02．19 当地时间2月18日，礼来公司公布了一项最新研究结果，显示出该公司的减重药替尔泊肽在肥胖合并自 身免疫性疾病方面的潜力。 一项针对274名银屑病患者的后期研究数据显示，使用替尔泊肽与该公司现有生物制剂依奇珠单抗联合 治疗的效果优于单独使用依奇珠单抗的疗效，并且联合治疗可同时实现减轻皮肤症状及体重减轻的双重 效果。 与此同时，随着礼来的口服减重药即将获批，双方在口服减重制剂领域的竞争已经开打。根据一份上周 公布的备案文件，礼来正在为口服减重药大举备货，公司预上市库存规模已达15亿美元，较去年同期的 5.5亿美元大幅增长。 微信编辑 | 雨林 责任编辑：王珂 2026.02．19 数据显示，在治疗36周时，约27.1%接受联合疗法的患者达到了银屑病完全清除的治疗目标，同时实现 10%的体重减轻；而单独使用依奇珠单抗的患者达到治疗目标的比例仅5.8%。 银屑病是一种慢性自身免疫性疾病，会导致皮肤上出现瘙痒、鳞屑斑块。这项研究结果显示了此类减重 药在治疗肥胖合并症方面的潜力，大部分肥胖患者还伴有至少一种与体重相关的合并症。 目前，礼来及主要竞争对手诺和诺德正在多个市场针对多种减重疗法新适应症方面展 ...

目前，礼来及主要竞争对手诺和诺德正在多个市场针对多种减重疗法新适应症方面展开激烈竞逐。 与此同时，随着礼来的口服减重药即将获批，双方在口服减重制剂领域的竞争已经开打。根据一份上周 公布的备案文件，礼来正在为口服减重药大举备货，公司预上市库存规模已达15亿美元，较去年同期的 5.5亿美元大幅增长。 银屑病是一种慢性自身免疫性疾病，会导致皮肤上出现瘙痒、鳞屑斑块。这项研究结果显示了此类减重 药在治疗肥胖合并症方面的潜力，大部分肥胖患者还伴有至少一种与体重相关的合并症。 目前，礼来及主要竞争对手诺和诺德正在多个市场针对多种减重疗法新适应症方面展开激烈竞逐。 新适应症的开拓意味着患者范围的扩大。就在上周，替尔泊肽获得中国国家药品监督管理局批准，新增 用于成人2型糖尿病（T2DM）单药治疗。此前，替尔泊肽用于接受二甲双胍和（或）磺脲类药物治疗 血糖仍控制不佳的成人2型糖尿病患者。 在欧洲市场，诺和诺德减重药物司美格鲁肽7.2mg更高剂量疗法也于本周获得批准，为医生和患者提供 了更多治疗选择。 当地时间2月18日，礼来公司公布了一项最新研究结果，显示出该公司的减重药替尔泊肽在肥胖合并自 身免疫性疾病方面的潜力。 一项针对 ...

Core Insights - Novo Nordisk has received European Commission approval for a new 7.2 mg once-weekly maintenance dose of Wegovy for adults with obesity, providing an additional treatment option for patients needing further weight reduction after the 2.4 mg dose [1][5] Group 1: Approval and Treatment Options - The 7.2 mg dose can be prescribed as three 2.4 mg injections during a single weekly session, with a regulatory application submitted for a dedicated 7.2 mg single-dose pen [2] - Wegovy is now available in all 27 EU member states in various strengths, including the newly approved 7.2 mg dose, and is already marketed in the UK [3] Group 2: Efficacy and Study Results - The phase III STEP UP study indicated that patients receiving the 7.2 mg dose achieved an average weight loss of 20.7% over 72 weeks, compared to 17.5% with the 2.4 mg dose [6][5] - Approximately 33.2% of patients on the 7.2 mg dose lost at least 25% of their weight, with most weight loss attributed to fat mass reduction while maintaining muscle function [7] Group 3: Safety and Tolerability - The safety profile of the 7.2 mg dose is consistent with the 2.4 mg dose, with common side effects being mild to moderate [8] Group 4: Market Context - Novo Nordisk shares have decreased by 9.9% over the past six months, contrasting with the industry's growth of 27.4% [4]